The FDA granted regenerative medicine advanced therapy designation to RTx-015 for the treatment of retinitis pigmentosa.

Kiora Pharmaceuticals (NASDAQ: KPRX) today announced the publication of the results from its Phase 1 ABACUS-1 study of KIO-301 in Nature Medicine. The publication adds clinical detail to a program ...

Retinitis pigmentosa is a devastating diagnosis. This condition can leave optometrists and ophthalmologists scrambling as they attempt to explain possible treatment options, none of which are very ...

One night, Tomás realized something was seriously wrong. He went for a stroll, along the same paths near his village that he ...

Kiora Pharmaceuticals (NASDAQ: KPRX) today announced the publication of the results from its Phase 1 ABACUS-1 study of KIO-301 in Nature Medicine. The ...

Retinitis pigmentosa is characterised by changes in the pigment layer of the retina. The pigment layer of the retina invades and damages the nerve layer and with time it affects the blood vessels of ...

RMAT designation enables intensified FDA engagement and potential accelerated pathways, implying preliminary clinical evidence for RTx-015 despite absent peer-reviewed efficacy details, endpoints, and ...

Retinitis pigmentosa is one of the commonest forms of inherited retina degenerative blindness worldwide. With the advent of molecular technologies it has become easier to identify the genetic defects ...

Dublin, April 21, 2025 (GLOBE NEWSWIRE) -- The "Retinitis Pigmentosa Treatment Market Report and Forecast 2024-2032" has been added to ResearchAndMarkets.com's offering. The retinitis pigmentosa ...

Dublin, June 26, 2025 (GLOBE NEWSWIRE) -- The "Retinitis Pigmentosa Market Opportunities and Strategies to 2034" report has been added to ResearchAndMarkets.com's offering. This report describes and ...